Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Background: Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification. Methods: Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid. Results: No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these. Conclusions: Phage treatment of Mycobacterium infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“successfully used to treat chronic, drug-resistant infections of M. abscessus (177–179)”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [178]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Phages have also been explored as diagnostic tools, and successfully used to treat chronic, drug-resistant infections of M. abscessus (177–179).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [178]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dedrick, R. M., Guerrero-Bustamante, C. A., Garlena, R. A., Russell, D. A., Ford, K., Harris, K., Gilmour, K. C., Soothill, J., Jacobs-Sera, D., Schooley, R. T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0437-z · Cited by 1,410
Self-citationSchooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Self-citationJault, P., Leclerc, T., Jennes, S., Pirnay, J. P., Que, Y.-A., Resch, G., Rousseau, A. F., Ravat, F., Carsin, H., Le Floch, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30482-1 · Cited by 874
Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1125 · Cited by 786
Bustamante, J., Boisson-Dupuis, S., Abel, L., & Casanova, J.-L. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.09.008 · Cited by 684
Phage Therapy for Antibiotic-Resistant Bacterial Infections
Hatfull, G. F., Dedrick, R. M., & Schooley, R. T. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-080219-122208 · Cited by 571
Self-citationSarker, S. A., Sultana, S., Reuteler, G., Moine, D., Descombes, P., Charton, F., Bourdin, G., McCallin, S., Ngom-Bru, C., Neville, T., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.023 · Cited by 533
Phage treatment of an aortic graft infected with Pseudomonas aeruginosa
Chan, B. K., Turner, P. E., Kim, S., Mojibian, H. R., Elefteriades, J. A., & Narayan, D. (2018) · Evolution, Medicine, and Public Health · doi:10.1093/emph/eoy005 · Cited by 501
Aslam, S., Lampley, E., Wooten, D., Karris, M., Benson, C., Strathdee, S., & Schooley, R. T. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa389 · Cited by 342
Self-citationNick, J. A., Dedrick, R. M., Gray, A. L., Vladar, E. K., Smith, B. E., Freeman, K. G., Malcolm, K. C., Epperson, L. E., Hasan, N. A., Hendrix, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.024 · Cited by 251 · cited 1×
“chelonae skin infection (patient 16); details of patients 15 and 16 were recently reported [22, 23].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Guerrero-Bustamante, 2021, Toward a phage cocktail for tuberculosis: susceptibility and tuberculocidal action of mycobacteriophages against diverse Mycobacterium tuberculosis strains, mBio, 12, e00973-21, 10.1128/mbio.00973-21 · DOI · Paper page
Cited by
Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817
Self-citationPirnay, J.-P., Djebara, S., Steurs, G., Griselain, J., Cochez, C., De Soir, S., Glonti, T., Spiessens, A., Vanden Berghe, E., Green, S., et al. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01705-x · Cited by 474
Bacterial persisters: molecular mechanisms and therapeutic development
Niu, H., Gu, J., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01866-5 · Cited by 310
The spread of antibiotic resistance to humans and potential protection strategies
Ding, D., Wang, B., Zhang, X., Zhang, J., Zhang, H., Liu, X., Gao, Z., & Yu, Z. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.114734 · Cited by 223
Phage Therapy—Challenges, Opportunities and Future Prospects
Zalewska-Piątek, B. (2023) · Pharmaceuticals · doi:10.3390/ph16121638 · Cited by 173
Mycobacterium smegmatis: The Vanguard of Mycobacterial Research
Sparks, I. L., Derbyshire, K. M., Jacobs, W. R., & Morita, Y. S. (2023) · Journal of Bacteriology · doi:10.1128/jb.00337-22 · Cited by 149
Translating phage therapy into the clinic: Recent accomplishments but continuing challenges
Fabijan, A. P., Iredell, J. R., Danis-Wlodarczyk, K. M., Kebriaei, R., & Abedon, S. T. (2023) · PLoS Biology · doi:10.1371/journal.pbio.3002119 · Cited by 147
Self-citationKim, M. K., Suh, G. A., Cullen, G. D., Rodriguez, S. P., Dharmaraj, T., Chang, T. H. W., Li, Z., Chen, Q., Green, S. I., Lavigne, R., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci187996 · Cited by 144
Karnwal, A., Jassim, A. Y., Mohammed, A. A., Al-Tawaha, A. R., Selvaraj, M., & Malik, T. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1517772 · Cited by 135
Berkson, J. D., Wate, C. E., Allen, G., Schubert, A. M., Dunbar, K. E., Coryell, M. P., Sava, R. L., Gao, Y. S., Hastie, J. L., Smith, E. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47192-w · Cited by 127
Phage engineering and phage‐assisted CRISPR‐Cas delivery to combat multidrug‐resistant pathogens
Khambhati, K., Bhattacharjee, G., Gohil, N., Dhanoa, G. K., Sagona, A. P., Mani, I., Bui, N. L., Chu, D., Karapurkar, J. K., Jang, S. H., et al. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10381 · Cited by 126
Immunogenicity of bacteriophages
Champagne-Jorgensen, K., Luong, T., Darby, T., & Roach, D. R. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.04.008 · Cited by 115
Inhibitors of bacterial immune systems: discovery, mechanisms and applications
Mayo-Muñoz, D., Pinilla‐Redondo, R., Camara-Wilpert, S., Birkholz, N., & Fineran, P. C. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-023-00676-9 · Cited by 105
Treatment for non-tuberculous mycobacteria: challenges and prospects
Conyers, L. E., & Saunders, B. M. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1394220 · Cited by 97
Bacteriophage and Bacterial Susceptibility, Resistance, and Tolerance to Antibiotics
Chen, Q., Dharmaraj, T., Cai, P. C., Burgener, E. B., Haddock, N. L., Spakowitz, A. J., & Bollyky, P. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071425 · Cited by 94
Alternative therapeutics to control antimicrobial resistance: a general perspective
Singha, B., Singh, V., & Soni, V. (2024) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2024.1385460 · Cited by 91
A perfect fit: Bacteriophage receptor-binding proteins for diagnostic and therapeutic applications
Klumpp, J., Dunne, M., & Loessner, M. J. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102240 · Cited by 84
Tran, N. N., Morrisette, T., Jorgensen, S. C. J., Orench‐Benvenutti, J. M., & Kebriaei, R. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2806 · Cited by 82
Weiner, I. N., Kahan-Hanum, M., Buchshtab, N., Zelcbuch, L., Navok, S., Sherman, I., Nicenboim, J., Axelrod, T., Berko-Ashur, D., Olshina, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60598-4 · Cited by 80
Huang, H., Jiang, J., Wang, X., Jiang, K., & Cao, H. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102428 · Cited by 78
Skurnik, M., Alkalay‐Oren, S., Boon, M., Clokie, M. R. J., Sicheritz‐Pontén, T., Dąbrowska, K., Hatfull, G. F., Hazan, R., Jalasvuori, M., Kiljunen, S., et al. (2025) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00377-5 · Cited by 77
Self-citationKoncz, M., Stirling, T., Mehdi, H. H., Méhi, O., Eszenyi, B., Asbóth, A., Apjok, G., Tóth, Á., Orosz, L. I., Vásárhelyi, B. M., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.009 · Cited by 76
Mycobacteriophages: From Petri dish to patient
Hatfull, G. F. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010602 · Cited by 74
Self-citationThe Medicinal Phage—Regulatory Roadmap for Phage Therapy under EU Pharmaceutical Legislation
Faltus, T. (2024) · Viruses · doi:10.3390/v16030443 · Cited by 72
Mycobacterium abscessus: It’s Complex
Abdelaal, H. F. M., Chan, E. D., Young, L., Baldwin, S. L., & Coler, R. N. (2022) · Microorganisms · doi:10.3390/microorganisms10071454 · Cited by 71
Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients
Bernabéu-Gimeno, M., Pardo-Freire, M., Chan, B. K., Turner, P. E., Gil-Brusola, A., Pérez‐Tarazona, S., Carrasco‐Hernández, L., Quintana‐Gallego, E., & Domingo‐Calap, P. (2024) · Med · doi:10.1016/j.medj.2024.05.017 · Cited by 66
Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects
Nguyen, M.-V. H., Haas, M. K., Kasperbauer, S. H., de Moura, V. C. N., Eddy, J. J., Mitchell, J. D., Khare, R., Griffith, D. E., Chan, E. D., & Daley, C. L. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae421 · Cited by 65
The Future of Clinical Phage Therapy in the United Kingdom
Jones, J. D., Trippett, C., Suleman, M., Clokie, M. R. J., & Clark, J. R. (2023) · Viruses · doi:10.3390/v15030721 · Cited by 63
Ali, Y., Inusa, I., Sanghvi, G. V., Mandaliya, V. B., & Bishoyi, A. K. (2023) · Microbial Pathogenesis · doi:10.1016/j.micpath.2023.106199 · Cited by 63
Phage Therapy for Nontuberculous Mycobacteria: Challenges and Opportunities
Hatfull, G. F. (2022) · Pulmonary Therapy · doi:10.1007/s41030-022-00210-y · Cited by 62
Self-citationBacteriophage therapy for the treatment of Mycobacterium tuberculosis infections in humanized mice
Yang, F., Labani‐Motlagh, A., Bohórquez, J. A., Moreira, J. D., Ansari, D., Patel, S., Spagnolo, F., Florence, J., Vankayalapati, A., Sakai, T., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06006-x · Cited by 59
Yerushalmy, O., Braunstein, R., Alkalay‐Oren, S., Rimon, A., Coppenhagen‐Glazer, S., Onallah, H., Nir‐Paz, R., & Hazan, R. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad514 · Cited by 58
Nir‐Paz, R., Onallah, H., Dekel, M., Gellman, Y. N., Haze, A., Ben‐Ami, R., Braunstein, R., Hazan, R., Dror, D., Oster, Y., et al. (2024) · Med · doi:10.1016/j.medj.2024.11.018 · Cited by 47
Yakoup, A. Y., Kamel, A. G., Elbermawy, Y., Abdelsattar, A. S., & El‐Shibiny, A. (2024) · Scientific Reports · doi:10.1038/s41598-023-50548-9 · Cited by 44
Borin, J. M., Lee, J. J., Gerbino, K. R., & Meyer, J. R. (2022) · Evolutionary Applications · doi:10.1111/eva.13518 · Cited by 43
Contemporary Pharmacotherapies for Nontuberculosis Mycobacterial Infections: A Narrative Review
Johnson, T. M., Byrd, T. F., Drummond, W. K., Childs‐Kean, L. M., Mahoney, M. V. G., Pearson, J. C., & Rivera, C. G. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00750-5 · Cited by 43
Mycobacterium abscessus Infections in Cystic Fibrosis Individuals: A Review on Therapeutic Options
Recchia, D., Stelitano, G., Stamilla, A., Lorenzo-Gutiérrez, D., Degiacomi, G., Chiarelli, L. R., & Pasca, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054635 · Cited by 42
Bacteriophage infection and killing of intracellular Mycobacterium abscessus
Schmalstig, A. A., Wiggins, A., Badillo, D., Wetzel, K. S., Hatfull, G. F., & Braunstein, M. (2023) · mBio · doi:10.1128/mbio.02924-23 · Cited by 40
Self-citationKang, D., Bagchi, D., & Chen, I. A. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300355 · Cited by 39
SEA-PHAGES and SEA-GENES: Advancing Virology and Science Education
Heller, D. M., Sivanathan, V., Asai, D. J., & Hatfull, G. F. (2024) · Annual Review of Virology · doi:10.1146/annurev-virology-113023-110757 · Cited by 39
Self-citationPhage Therapy for Respiratory Infections: Opportunities and Challenges
Khosravi, A., Chen, Q., Echterhof, A., Koff, J. L., & Bollyky, P. L. (2024) · Lung · doi:10.1007/s00408-024-00700-7 · Cited by 39
Therapeutic Phage Monitoring: A Review
Bosco, K., Lynch, S. A., Sandaradura, I., & Khatami, A. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad497 · Cited by 38
Self-citationTherapeutically useful mycobacteriophages BPs and Muddy require trehalose polyphleates
Wetzel, K. S., Illouz, M., Abad, L., Aull, H. G., Russell, D. A., Garlena, R. A., Cristinziano, M., Malmsheimer, S., Chalut, C., Hatfull, G. F., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01451-6 · Cited by 37
Self-citationPhages and phage-borne enzymes as new antibacterial agents
McCallin, S. E., Drulis‐Kawa, Z., Ferry, T., Pirnay, J., & Nir‐Paz, R. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.10.018 · Cited by 37
Dedrick, R. M., Abad, L., Storey, N., Kaganovsky, A., Smith, B. E., Aull, H. G., Cristinziano, M., Morkowska, A., Murthy, S. E., Loebinger, M. R., et al. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.06.026 · Cited by 37
Self-citationIntegrative systems biology approaches for analyzing microbiome dysbiosis and species interactions
Rehman, S. S. U., Nasar, M. I., Mesquita, C. S., Khodor, S. A., Notebaart, R. A., Ott, S., Mundra, S., Arasardanam, R. P., Muhammad, K., & Alam, M. T. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf323 · Cited by 36
Rapid hydrogel-based phage susceptibility test for pathogenic bacteria
Patpatia, S., Schaedig, E., Dirks, A., Paasonen, L., Skurnik, M., & Kiljunen, S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1032052 · Cited by 36
Self-citationPhage-specific antibodies: are they a hurdle for the success of phage therapy?
Washizaki, A., Sakiyama, A., & Ando, H. (2024) · Essays in Biochemistry · doi:10.1042/ebc20240024 · Cited by 35
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100018 · Cited by 35
Migration of surface-associated microbial communities in spaceflight habitats
Marra, D., Karapantsios, T. D., Caserta, S., Secchi, E., Hołyńska, M., Labarthe, S., Polizzi, B., Ortega, S., Kostoglou, M., Lasseur, C., et al. (2023) · Biofilm · doi:10.1016/j.bioflm.2023.100109 · Cited by 33
Virion glycosylation influences mycobacteriophage immune recognition
Freeman, K. G., Robotham, A. C., Parks, O. B., Abad, L., Jacobs‐Sera, D., Lauer, M. J., Podgorski, J. M., Zhang, Y., Williams, J. V., White, S. J., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.028 · Cited by 33
Self-citationCalcagno, A., Coppola, N., Sarmati, L., Tadolini, M., Parrella, R., Matteelli, A., Riccardi, N., Trezzi, M., Biagio, A. D., Pirriatore, V., et al. (2024) · Infection · doi:10.1007/s15010-024-02183-3 · Cited by 33
Dulberger, C. L., Guerrero-Bustamante, C. A., Owen, S. V., Wilson, S., Wuo, M. G., Garlena, R. A., Serpa, L. A., Russell, D. A., Zhu, J., Braunecker, B. J., et al. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01333-x · Cited by 32
Self-citationCRISPR–Cas therapies targeting bacteria
Benz, F., Beamud, B., Laurenceau, R., Maire, A., Duportet, X., Decrulle, A. L., & Bikard, D. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00311-8 · Cited by 32
Clinical phage microbiology: a narrative summary
Suh, G. A., & Patel, R. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.02.006 · Cited by 32
Structure and infection dynamics of mycobacteriophage Bxb1
Freeman, K. G., Mondal, S., Macale, L. S., Podgorski, J. M., White, S. J., Silva, B. H., Ortiz, V., Huet, A., Perez, R. J., Narsico, J. T., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.027 · Cited by 31
Self-citationPhage therapy: breathing new tactics into lower respiratory tract infection treatments
Vaezi, A., Healy, T., Ebrahimi, G., Rezvankhah, S., Shahraki, A. H., & Mirsaeidi, M. S. (2024) · European Respiratory Review · doi:10.1183/16000617.0029-2024 · Cited by 30
Dartois, V. A., Bonfield, T. L., Boyce, J. P., Daley, C. L., Dick, T., Juarrero, M. G., Gupta, S., Kramnik, I., Lamichhane, G., Laughon, B. E., et al. (2024) · Tuberculosis · doi:10.1016/j.tube.2024.102503 · Cited by 29
The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges
Ghanem, R., Youf, R., Haute, T., Buin, X., Riool, M., Pourchez, J., & Montier, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.017 · Cited by 28
Alternatives to Antibiotics against Mycobacterium abscessus
Broncano-Lavado, A., Senhaji-Kacha, A., Santamaría-Corral, G., Esteban, J., & García‐Quintanilla, M. (2022) · Antibiotics · doi:10.3390/antibiotics11101322 · Cited by 28
Do Anti-Phage Antibodies Persist after Phage Therapy? A Preliminary Report
Łusiak-Szelachowska, M., Międzybrodzki, R., Rogóż, P., Weber‐Dąbrowska, B., Żaczek, M., & Górski, A. (2022) · Antibiotics · doi:10.3390/antibiotics11101358 · Cited by 28
Manohar, P., Loh, B., Turner, D., Tamizhselvi, R., Mathankumar, M., Elangovan, N., Nachimuthu, R., & Leptihn, S. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1344962 · Cited by 28
Phage to ESKAPE: Personalizing Therapy for MDR Infections—A Comprehensive Clinical Review
Marıno, A., Stracquadanio, S., Cosentino, F., Maraolo, A. E., Colpani, A., VITO, A. D., Geremia, N., Nicolosi, A., Oliva, A., Cacopardo, B. S., et al. (2025) · Pathogens · doi:10.3390/pathogens14101011 · Cited by 27
Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods
Wacnik, M., Hauza, E., Skaradzińska, A., & Śliwka, P. (2026) · Molecules · doi:10.3390/molecules31020324 · Cited by 26
The Post-Antibiotic Era: A New Dawn for Bacteriophages
Jin, Y., Li, W., Zhang, H., Ba, X., Li, Z., & Zhou, J. (2023) · Biology · doi:10.3390/biology12050681 · Cited by 26
Fletcher, J., Manley, R., Fitch, C., Bugert, C., Moore, K., Farbos, A., Michelsen, M. L., Alathari, S., Senior, N. J., Mills, A., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12020253 · Cited by 26
Self-citationCristinziano, M., Shashkina, E., Chen, L., Xiao, J., Miller, M. B., Doligalski, C. T., Coakley, R. D., Lobo, L. J., Footer, B. W., Bartelt, L. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54666-4 · Cited by 26
Self-citationGainey, A. B., Daniels, R., Burch, A., Hawn, J., Fackler, J. R., Biswas, B., & Brownstein, M. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003735 · Cited by 25
Self-citationCombating Antimicrobial Resistance: A paradigm shift from general to precision medicine
Ahmed, F., Shamim, N. J., Das, A., Sharma, H. K., Grewal, A. S., Pandita, D., & Lather, V. (2024) · Chemical Biology Letters · doi:10.62110/sciencein.cbl.2024.v11.662 · Cited by 25
Computational host range prediction—The good, the bad, and the ugly
Howell, A. A., Versoza, C. J., & Pfeifer, S. P. (2023) · Virus Evolution · doi:10.1093/ve/vead083 · Cited by 24
Cocorullo, M., Stelitano, G., & Chiarelli, L. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158321 · Cited by 24
Zhang, F., Kamm, M. A., Wu, X., Kao, D. H., Borody, T. J., Chen, L. A., He, X., Fischer, M., Wong, S. H., Ng, S. C., et al. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16947 · Cited by 23
Phage therapy could be key to conquering persistent bacterial lung infections in children
Shein, A. M. S., Hongsing, P., Khatib, A. N., Phattharapornjaroen, P., Miyanaga, K., Cui, L., Shibuya, K., Amarasiri, M., Monk, P. N., Kicic, A., et al. (2024) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00045-4 · Cited by 23
Duan, X., Liu, W., Xiao, Y., Rao, M., Ji, L., Wan, X., Han, S., Lin, Z., Liu, H., Chen, P., et al. (2025) · Emerging Microbes & Infections · doi:10.1080/22221751.2025.2451048 · Cited by 22
Ethical argument for establishing good manufacturing practice for phage therapy in the UK
Suleman, M., Clark, J. R., Bull, S., & Jones, J. D. (2024) · Journal of Medical Ethics · doi:10.1136/jme-2023-109423 · Cited by 22
Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?
Ling, K., Stick, S. M., & Kicic, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1088494 · Cited by 22
Bacterial restriction-modification systems: mechanisms of defense against phage infection
Kang, H., Gao, A., & Zhu, Y. (2025) · Biophysics Reports · doi:10.52601/bpr.2025.240070 · Cited by 21
Le, H. T., Venturini, C., Fajardo-Lubian, A., Bowring, B. G., Iredell, J. R., George, J., Ahlenstiel, G., & Read, S. A. (2025) · European Journal of Immunology · doi:10.1002/eji.202451543 · Cited by 21
Self-citationIntrapulmonary Treatment with Mycobacteriophage LysB Rapidly Reduces Mycobacterium abscessus Burden
Hurst-Hess, K. R., Walz, A., Yang, Y., McGuirk, H., Juarrero, M. G., Hatfull, G. F., Ghosh, P., & Ojha, A. K. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00162-23 · Cited by 21
Self-citationAdvances in Engineered Phages for Disease Treatment
Hou, X. L., Lin, Z., Fu, L., Lu, J., Guo, P., Zhang, Y., Zheng, D., & Ma, G. (2025) · Small Methods · doi:10.1002/smtd.202401611 · Cited by 20
Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States
Kline, A., Güemes, A. G. C., Yore, J. B., Ghose, C., Tyne, D. V., Whiteson, K., & Pride, D. T. (2025) · Antibiotics · doi:10.3390/antibiotics14060553 · Cited by 20
Hatfull, G. F. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2523344122 · Cited by 20
Self-citationBacterial resistance to phage therapy: Mechanisms and strategies to overcome it
Karamlou, S., Aghajani, E., Familsamavati, M., Azad, N. F., Arayesh, S., & Mohsenipour, Z. (2025) · Current Molecular Pharmacology · doi:10.1016/j.cmp.2025.11.003 · Cited by 20
Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections
Ouyang, X., Li, X., Song, J., Wang, H., Wang, S., Ren, F., Li, Z., & Song, N. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1277178 · Cited by 20
Alternative therapies against Mycobacterium abscessus infections
Palucci, I., & Delogu, G. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.10.001 · Cited by 20
Pye, H. V., Krishnamurthi, R., Cook, R., & Adriaenssens, E. M. (2024) · Essays in Biochemistry · doi:10.1042/ebc20240012 · Cited by 20
Nucleus-forming jumbophage PhiKZ therapeutically outcompetes non-nucleus-forming jumbophage Callisto
Naknaen, A., Samernate, T., Saeju, P., Nonejuie, P., & Chaikeeratisak, V. (2024) · iScience · doi:10.1016/j.isci.2024.109790 · Cited by 19
Zheng, X., Liu, M., Li, P., Xu, S., Chen, L., Xu, G., Pang, X., Du, H., zheng, Y., Huo, X., et al. (2024) · Virologica Sinica · doi:10.1016/j.virs.2024.08.002 · Cited by 19
Juliet, R., Loganathan, A., Neeravi, A., Bakthavatchalam, Y. D., Veeraraghavan, B., Manohar, P., & Nachimuthu, R. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1391777 · Cited by 18
Gut microbiota: a crucial player in the combat against tuberculosis
Jie, L., Chen, D., Yan, Y., Pi, J., Xu, J.-F., Chen, L., & Zheng, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1442095 · Cited by 18
Skin and soft tissue infections due to rapidly growing mycobacteria
Sepulcri, C., Vena, A., & Bassetti, M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000905 · Cited by 18
Gorzynski, M., Ville, K. D., Week, T., Jaramillo, T., & Danelishvili, L. (2023) · Biomedicines · doi:10.3390/biomedicines11051379 · Cited by 18
Friedland, A. E., Maziarz, E. K., Wolfe, C. R., Patel, C. B., Patel, P. A., Milano, C. A., Schroder, J. N., Daneshmand, M. A., Wallace, R. J., Alexander, B. D., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.04.009 · Cited by 17
Phage Milagro: a platform for engineering a broad host range virulent phage for Burkholderia
Yao, G. W., Le, T., Korn, A. M., Peterson, H. N., Liu, M., Gonzalez, C. F., & Gill, J. J. (2023) · Journal of Virology · doi:10.1128/jvi.00850-23 · Cited by 17
Lewis, J. M., Williams, J., & Sagona, A. P. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231289 · Cited by 17
Phage Therapy for Orthopaedic Infections: The First Three Cases from the United Kingdom
Munteanu, D. I., Dunn, J., Apjok, G., Kintses, B., Griselain, J., Steurs, G., Cochez, C., Djebara, S., Merabishvili, M., Pirnay, J., et al. (2025) · Antibiotics · doi:10.3390/antibiotics14020114 · Cited by 17
Isolation and Characterization of the Lytic Pseudoxanthomonas kaohsiungensi Phage PW916
Wen, C., Ai, C., Lu, S., Yang, Q., Liao, H., & Zhou, S. (2022) · Viruses · doi:10.3390/v14081709 · Cited by 17
Nguyen, M.-V. H., & Daley, C. L. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2023.06.009 · Cited by 17
The heterogenous and diverse population of prophages in Mycobacterium genomes
Abad, L., Gauthier, C. H., Florian, I., Jacobs‐Sera, D., & Hatfull, G. F. (2023) · mSystems · doi:10.1128/msystems.00446-23 · Cited by 17
Self-citationNanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy
Dorta-Gorrín, A., Salgueiriño, V., & García-Hevia, L. (2026) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107660 · Cited by 16
Metadata
- Authors
- Dedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., Gainey, A., Garcia, C. B., Robert George, C. R., Haidar, G., Ip, W., Iredell, J., Khatami, A., Little, J. S., Malmivaara, K., McMullan, B. J., Michalik, D. E., Moscatelli, A., Nick, J. A., Tupayachi Ortiz, M. G., Polenakovik, H. M., Robinson, P. D., Skurnik, M., Solomon, D. A., Soothill, J., Spencer, H., Wark, P., Worth, A., Schooley, R. T., Benson, C. A., & Hatfull, G. F.
- Affiliations
- University of Pittsburgh (US)
- Department of Biological Sciences, University of Pittsburgh , Pittsburgh, Pennsylvania , USA
- UNSW Sydney (AU)
- Inova Fairfax Hospital , Falls Church, Virginia , USA
- Johns Hopkins University (US)
- National Jewish Health (US)
- Division of Infectious Diseases, University of North Carolina , Chapel Hill, North Carolina , USA
- Prisma Health (US)
- Department of Respiratory Disease, Hospital Universitari Vall d’Hebron , Barcelona , Spain
- New South Wales Health Pathology Microbiology, John Hunter Hospital , New Lambton, New South Wales , Australia
- Great Ormond Street Hospital (GB)
- Sydney Children's Hospital (AU)
- Children's Hospital at Westmead (AU)
- Brigham and Women's Hospital (US)
- Miller Children's & Women's Hospital (US)
- Istituto Giannina Gaslini (IT)
- Department of Medicine, Division of Pulmonary and Critical Care Medicine, Miller School of Medicine, University of Miami , Miami, Florida , USA
- Wright State University (US)
- University of Helsinki (FI)
- Hunter Medical Research Institute (AU)
- University of California San Diego (US)
- Corresponding author
- Hatfull, Graham F
- ORCID
- Dedrick, Rebekah M
- Smith, Bailey E
- Freeman, Krista G
- Belessis, Yvonne
- Cohen, Keira A
- Davidson, Rebecca M
- Gainey, Andrew
- Haidar, Ghady
- Ip, Winnie
- Iredell, Jonathan
- Khatami, Ameneh
- Little, Jessica S
- McMullan, Brendan J
- Michalik, David E
- Moscatelli, Andrea
- Nick, Jerry A
- Polenakovik, Hari M
- Robinson, Paul D
- Skurnik, Mikael
- Solomon, Daniel A
- Spencer, Helen
- Wark, Peter
- Worth, Austen
- Schooley, Robert T
- Benson, Constance A
- Hatfull, Graham F
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-06-09
- Volume
- 76
- Issue
- 1
- Pages
- 103-112
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC9825826
- OpenAlex
- W4281760779
- Cited by
- 344
- References
- 23
- Citations by year
- 2026: 74 · 2025: 89 · 2024: 91 · 2023: 72 · 2022: 18
- FWCI
- 35.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Infectious Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Työväentutkimus Vuosikirja (submittedVersion)
- Funders
- Howard Hughes Medical Institute (GT12053)
- Cystic Fibrosis Foundation (HATFUL19GO, NICK20Y2-SVC, NICK20Y2-OUT)
- National Heart, Lung, and Blood Institute (K08 HL139994-01)
- Burroughs Wellcome Fund (HL146228, NICK20Y2-SVC and NICK20Y2-OUT)
- NIH (GM131729, AI154546, R01HL146228)
- Jane and Aatos Erkko Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Keywords
- phage therapy, Mycobacterium abscessus, nontuberculous mycobacterial infection, cystic fibrosis, phage resistance, neutralizing antibodies, phage neutralization, compassionate use, adjunctive therapy
- MeSH terms
- Phage Therapy, Anti-Bacterial Agents, Bacteriophages, Cystic Fibrosis, Pharmaceutical Preparations, Humans, Mycobacterium, Mycobacterium Infections, Nontuberculous, Compassionate Use Trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.